Type 2 Diabetes

Empagliflozin Impact on Life Expectancy Examined in T2DM Patients With CVD

Empagliflozin Impact on Life Expectancy Examined in T2DM Patients With CVD

By

For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.

ADA, EASD Issue New Recommendations for Type 2 Diabetes

ADA, EASD Issue New Recommendations for Type 2 Diabetes

Recommendations for the management of type 2 diabetes have been updated, according to a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes.

Lixisenatide Cuts Kidney Damage in Type 2 Diabetes and Coronary Syndrome

Lixisenatide Cuts Kidney Damage in Type 2 Diabetes and Coronary Syndrome

Lixisenatide reduces progression of urinary albumin-creatinine ratio in patients with macroalbuminuria.

Lower Hypoglycemia Risk, Greater Weight Loss With SGLT2 Inhibitor, Sulfonylurea in T2D

Lower Hypoglycemia Risk, Greater Weight Loss With SGLT2 Inhibitor, Sulfonylurea in T2D

SGLT-2i exhibited superior effects in terms of weight loss and did not increase the risk for hypoglycemia in dual therapy with sulfonylurea.

Higher Aldosterone Levels Tied to Incident Type 2 Diabetes Risk

Higher Aldosterone Levels Tied to Incident Type 2 Diabetes Risk

Racial/ethnic differences seen in the association of aldosterone with incident type 2 diabetes.

WHO Issues Guidelines for Managing Diabetes in Low-Resource Settings

WHO Issues Guidelines for Managing Diabetes in Low-Resource Settings

WHO has developed guidelines for selecting therapy for treatment intensiļ¬cation in type 2 diabetes and on the use of insulin in type 1 and 2 diabetes in resource-poor settings.

Polypharmacy Therapy for Schizophrenia Increases Risk for Type 2 Diabetes

Polypharmacy Therapy for Schizophrenia Increases Risk for Type 2 Diabetes

Investigators aimed to assess the effect of psychotropic medications, BMI, duration of schizophrenia, number of hospitalizations, and physical activity on the risk for T2D.

Healthy Lifestyle With Diabetes Cuts Cardiovascular Risk

Healthy Lifestyle With Diabetes Cuts Cardiovascular Risk

Benefit seen for adoption of healthy lifestyle even after T2DM diagnosis made.

Bariatric surgery linked to significant reduction in microvascular complications of type 2 diabetes

Patients who received gastric bypass surgery had lower rates of diabetic neuropathy at follow up that remained stable throughout the study.

Fasting Insulin vs Hemoglobin A1c: Are We Getting It Right?

Fasting Insulin vs Hemoglobin A1c: Are We Getting It Right?

The early diagnosis and management of prediabetes will have a significant impact on patient outcomes and healthcare spending.

Insulin analogs compared to NPH not associated with reduced hypoglycemia-related hospitalizations

In this retrospective cohort study, for patients with type 2 diabetes, initiation of a basal insulin analog compared with NPH insulin was not associated with a reduced risk of hypoglycemia-related ED visits or hospital admissions.

Low-Carb Diet May Reduce HbA1c More Than Low-Fat Diet in T2D

Low-Carb Diet May Reduce HbA1c More Than Low-Fat Diet in T2D

Investigators compared low-carbohydrate with low-fat diet on glucose control and other metabolic and anthropometric variables in T2D.

Hepatic Markers Linked to Early Predictors of Type 2 Diabetes Risk in Women

Hepatic Markers Linked to Early Predictors of Type 2 Diabetes Risk in Women

Circulating hepatic markers may predict the risk for diabetes in women.

Independent Relationship Between CV Mortality, Oxidative DNA Damage in Type 2 Diabetes

Independent Relationship Between CV Mortality, Oxidative DNA Damage in Type 2 Diabetes

By

This represents the prospective study confirming an independent relationship between cardiovascular mortality and oxidative DNA damage in type 2 diabetes.

Basal Insulin Analogs vs NPH Insulin to Reduce Hypoglycemia-Linked ED Visits in T2D

Basal Insulin Analogs vs NPH Insulin to Reduce Hypoglycemia-Linked ED Visits in T2D

By

Compared with human neutral protamine Hagedorn insulin, basal insulin analogs do not reduce risk of hypoglycemia-linked ED visits or hospital admissions in T2D.

Link Between Bullous Pemphigoid and Dipeptidyl Peptidase-4 Inhibitors

Link Between Bullous Pemphigoid and Dipeptidyl Peptidase-4 Inhibitors

The relationship between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents

Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents

Investigators analyzed real world data to examine the risk for below-knee amputations in patients with type 2 diabetes taking canagliflozin vs other medications.

Age, Baseline HbA1c May Predict Glycemic Control in Newly Diagnosed Type 2 Diabetes

Age, Baseline HbA1c May Predict Glycemic Control in Newly Diagnosed Type 2 Diabetes

By

Investigators examined the effectiveness of oral agents vs insulin as an initial treatment option for people newly diagnosed with type 2 diabetes.

Liraglutide May Prevent Dementia in Elderly With Type 2 Diabetes

Liraglutide May Prevent Dementia in Elderly With Type 2 Diabetes

Investigators examined the efficacy of liraglutide for the prevention of dementia in elderly patients with type 2 diabetes.

Chronic Kidney Disease More Common in Type 2 Diabetes Than in Type 1 Diabetes

Chronic Kidney Disease More Common in Type 2 Diabetes Than in Type 1 Diabetes

By

Investigators examined the prevalence of chronic kidney disease in adults with type 1 diabetes compared with type 2 diabetes.

MEDI0382 Safe, Effective for Normalizing Glucose, Weight Loss in Type 2 Diabetes

MEDI0382 Safe, Effective for Normalizing Glucose, Weight Loss in Type 2 Diabetes

By

MEDI0382 reduced body weight and normalized fasting and postprandial blood glucose levels in patients with type 2 diabetes.

Type 2 Diabetes Does Not Affect Pneumonia Incidence, Outcomes After Stroke

Type 2 Diabetes Does Not Affect Pneumonia Incidence, Outcomes After Stroke

By

Investigators examined the incidence and outcomes of pneumonia in patients with acute ischemic stroke and type 2 diabetes.

Cancer Development Linked to Increased Diabetes Risk

Cancer Development Linked to Increased Diabetes Risk

Increased risk of subsequent diabetes independent of traditional diabetes risk factors

US Nursing Home Costs Due to Diabetes Vary Greatly by State

US Nursing Home Costs Due to Diabetes Vary Greatly by State

Per-person diabetes-attributable costs ranged from 374 in New Mexico to 1,610 in Washington, D.C.

Diabetes and Mortality: Comparing SGLT-2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors

Diabetes and Mortality: Comparing SGLT-2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors

By

For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists significantly reduce mortality rates compared with dipeptidyl peptidase 4 inhibitors.

Diabetes Prevalence by Type in the United States: CDC report

Diabetes Prevalence by Type in the United States: CDC report

By

The CDC conducted a study to estimate the prevalence of diagnosed diabetes among adults in 2016 by primary type.

Case Study in Diabetes: Fungal Infections

Case Study in Diabetes: Fungal Infections

A 68-year-old patient with type 2 diabetes presents to a urologist to evaluate funguria, and a CT scan showed right hydroureteronephrosis.

Inflammatory Bowel Disease Risk Associated with DPP-4 Inhibitor Use

Inflammatory Bowel Disease Risk Associated with DPP-4 Inhibitor Use

By

Patients with type 2 diabetes have a greater risk for developing inflammatory bowel disease when using dipeptidyl peptidase-4 inhibitors.

ACP supports higher HbA1c targets for pharmacotherapy in adults with T2D

ACP supports higher HbA1c targets for pharmacotherapy in adults with T2D

By

ACP responds to criticism from the ADA, the Endocrine Society, the AACE, and the AADE of guidance that clinicians should aim to achieve an HbA1c level between 7% and 8% in most people with type 2 diabetes.

High fiber diet beneficial for gut bacteria development in type 2 diabetes

High fiber diet beneficial for gut bacteria development in type 2 diabetes

A high fiber diet promotes gut bacteria that helps blood glucose control in patients with type 2 diabetes.

Sign Up for Free e-newsletters